2 completed, 2 withdrawn, 1 recruiting. 5 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 2, Withdrawn 2, Recruiting 1 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Port-Wine Stain: new trials by email Literature Review of Port-Wine Stain trials Research Report on Port-Wine Stain
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Efficacy and Safety of Light Dose in Subjects With PWB Treated With Hemoporfin PDT Hemopfin+Green Light, Vehicle+Green Light - Port-wine Birthmarks, Port-Wine Stain | Phase 2 | Recruiting | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | 84 | 2024-09-21 | 2026-03-03 |
| Treatment of Resistant Port-wine Stains With Bosentan and Pulsed Dye Laser: a Pilot Study Bosentan, Pulsed dye laser (PDL) - Port-wine Stains | Phase 2 | Completed | Centre Hospitalier Universitaire de Nice | 4 | 2014-04-01 | 2018-02-05 |
| Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS) Everolimus - Sturge Weber Syndrome | Phase 2 | Withdrawn | Baylor College of Medicine | 2014-04-01 | 2016-05-05 | |
| Combined Use of Pulsed Dye Laser and Topical Antiangiogenic Agents for Treatment of Port Wine Stain Birthmarks Topical Antiangiogenic, Pulsed Dye Laser - Port Wine Stain | Phase 1 / Phase 2 | Withdrawn | University of California, Irvine | 2009-11-01 | 2022-11-01 | |
| Measurement Skin Temperature During Pulsed Laser Exposure cooling spray during laser treatment - Port-Wine Stain | Phase 2 | Completed | University of California, Irvine | 118 | 2002-07-01 | 2022-11-01 |
Epilepsy (1) · Glaucoma (1) · Sturge-Weber Syndrome (1)
Congenital Abnormalities (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Skin Abnormalities (5) · Skin Diseases (5) · Skin and Connective Tissue Diseases (5) · Angiomatosis (1) · Brain Diseases (1) · Cardiovascular Diseases (1) · Central Nervous System Diseases (1) · Eye Diseases (1) · Hemangioma (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms, Vascular Tissue (1) · Nervous System Diseases (1)
Lasers, Dye (2) · Angiogenesis Inhibitors (1) · Bosentan (1) · Everolimus (1) · Laser Therapy (1)
University of California, Irvine (2) · Baylor College of Medicine (1) · Centre Hospitalier Universitaire de Nice (1) · Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (1)
United States (3) · France (1)
Angus A Wilfong, MD (1) · John S Nelson, M.D,PhD (1) · John S. Nelson, M.D., Ph.D (1)